Clinical Trial Update: Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma [Phase 2]

View source ↗

Summary

Phase 2 trial update for selumetinib in Neurofibromatosis Type 1 with cutaneous neurofibromas; study completed with results posted in late 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Neurofibroma
• Neurofibromatosis Type
• Optic Nerve Glioma

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Cutaneous Neurofibroma, Neurofibromatosis Type 1 | Phase 2 | Status: COMPLETED | Results posted: 2023-12-05